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A b s t r A c t
Brain natriuretic peptide (BNP) is a peptide hormone secreted by cardiomyocytes in 
response to atrial or ventricular wall stretch and/or pressure overload. It promotes a 
number of systemic effects, including vasodilatation, increase in urinary output and 
sodium excretion, as well as inhibition of the sympathetic nervous system and the 
renin–angiotensin–aldosterone system. Plasma BNP levels have been reported to be 
elevated in patients with left ventricular hypertrophy, congestive heart failure, acute 
coronary syndromes, atrial fibrillation, and impaired renal function. Moreover, ele-
vated BNP levels have been shown to be a strong predictor of morbidity and mortality 
in patients with heart failure. Interestingly, it has also been found that the N-terminal 
peptide of BNP is slightly superior to BNP for predicting death or re-hospitalization 
for heart failure. Presumably, it is the longer half-life of N-terminal fragment of brain-
type natriuretic peptide (NT-pro-BNP) that may promote it as a more accurate index 
of ventricular stress and therefore a better predictor of prognosis.
I N t r O D U c t I O N
Over the past few decades, exciting advances have been made in the field of cardiac 
biomarkers and their key role as important tools for diagnosis, risk stratification and 
therapeutic decision-making in patients with suspected acute coronary syndromes 
and other cardiovascular disease. According to the World Health Organization, a 
biomarker is defined as “any substance, structure, or process that can be measured in 
the body or its products and influence or predict the incidence of outcome or disease”.1 
It has been concluded that a biomarker is accepted as clinically useful when the fol-
lowing criteria are fulfilled: i) availability of accurate and repeated measurements at 
a reasonable cost with short turnaround times, ii) provision of information that is not 
available from a thorough clinical examination and iii) assistance in clinical decision 
making.2 Indeed, cardiac troponins T and I play an essential role for diagnostic work 
up in patients suffering from acute myocardial infarction (MI). 
Currently, researchers are investigating several promising new biomarkers, with 
the brain-type natriuretic peptide (BNP) being one with proved diagnostic usefulness 
in a great number of studies, which has thus progressed from benchside to clinical 
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ACE = angiotensin converting enzyme
ANP = atrial natriuretic peptide 
ARB = angiotensin II receptor blocker
ARNI = angiotensin receptor neprilysin 
inhibitor
BNP = brain-type natriuretic peptide
cGMP = cyclic guanosine monophosphate 
CNP = C-type natriuretic peptide
ECG = electrocardiogram
MI = myocardial infarction
MMP = matrix metalloproteinase 
NEP = neprilysin
NFAT = nuclear factor of activated T cells
NPR-A = natriuretic peptide receptor-A 
NT-pro-BNP = N-terminal fragment of 
brain-type natriuretic peptide 
PKG = protein kinase G
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FIgUre 1. Human brain natriuretic peptide (BNP) is produced as a 108 amino acid prohormone (proBNP-108), an inactive pro-
form, which is converted to the biologically active peptide BNP32, and an inactive N-terminal (NT)-pro-BNP through cleavage by a 
proteolytic enzyme, called corin.
application at the bedside. Specifically, BNP secreted by 
the cardiac ventricles has emerged as a novel biomarker for 
monitoring and prognosis of left ventricular dysfunction in 
hypertensive subjects. Besides, in recent studies, BNP has also 
been proposed as an independent marker for atrial fibrilla-
tion and cardioembolic stroke associated with poor clinical 
outcomes.3 In this review we are going to summarize existing 
data concerning the structural characteristics, the mode of 
action and the clinical significance of BNP and its N-terminal 
fragment (NT-pro-BNP) in the diagnosis and prediction of 
heart failure. Furthermore, we will review data assessing the 
validity of this biomarker in screening asymptomatic subjects 
at risk for heart failure.
s y N t h e s I s ,  A c t I O N ,  A N D  b N P 
c l e A r A N c e  b y  t h e  K I D N e y s
In recent years, researchers have isolated originally from 
porcine brain extracts a neurohormone named BNP, which 
along with atrial natriuretic peptide (ANP) and C-type natriu-
retic peptide (CNP) form a triple natriuretic peptide system 
of the heart muscle. All peptides share a similar amino-acid 
sequence homology. Heart failure, as well as renal insuf-
ficiency, constitute clinical conditions where the natriuretic 
peptide system can become activated.
It has been demonstrated that BNP is synthesized and 
secreted by the cardiomyocytes in response to increased 
myocardial wall stress. Data suggest that a significant amount 
of BNP is produced and released into the blood circulation 
by the human ventricles in contrast to ANP, which is mainly 
secreted by the atria, and is involved in fluid, electrolyte and 
vascular homeostasis.4,5 Specifically, it has been shown that 
BNP is produced by ventricular cardiomyocytes in response 
to pressure overload in the left ventricle as an inactive prohor-
mone, which is later cleaved by an enzyme called corin into the 
active hormone BNP and the inactive NT-pro-BNP4 (Fig. 1).
Human BNP is produced as a 108 amino acid prohormone 
(pro-BNP-108), an inactive proform, which is converted to 
the biologically active peptide BNP32, and an inactive N-
terminal (NT-pro-BNP) through cleavage by proteolytic en-
zymes. Previous studies have shown that both corin, a cardiac 
serine protease, and furin, a ubiquitous serine protease, are 
critical in mediating pro-BNP processing in cardiomyocytes.6 
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As far as we know, corin consists of 1042 amino acids with 
an integral transmembrane domain near the N-terminal 
region, and is mainly expressed in the normal human heart 
and kidney, especially in cells around the vasculature. On the 
other hand, furin is expressed in the Golgi apparatus of many 
types of cells.7 To gain insight into the sequence-specificity of 
furin- and corin- mediated pro-BNP processing, Semenov et 
al used non-glycosylated pro-BNP made in Escherichia Coli, 
and showed that furin cleaved pro-BNP at Arg-76, generating 
BNP1-32, whereas corin cleaved pro-BNP at Lys-79, gener-
ating BNP4-32.8 Another study clearly demonstrated that in 
cardiomyocytes pro-BNP processing is mediated by the corin 
enzyme at several different sites. This differed significantly 
from BNP-processing in human embryonic kidney (HEK) 293 
cells, where furin cleaved pro-BNP at a single residue (Arg-
76). Interestingly, corin also activates ANP.9 However, further 
studies are needed to provide insights into the biochemical 
basis of pro-BNP processing.
Following its secretion, BNP binds preferentially to the 
natriuretic peptide receptor-A (NPR-A) to exert its effect in 
the regulation of intravascular blood volume and vascular tone. 
Existing evidence suggests that BNP acts not only as a circulat-
ing hormone, but also as an autocrine and/or paracrine factor 
in order to exert its cardioprotective role against myocardial 
hypertrophy and fibrosis.10 Specifically, NPR-A is linked to 
guanylyl cyclase, which upon ligand binding upregulates cyclic 
guanosine monophosphate (cGMP) levels. Cyclic GMP is a 
key second messenger which in turn drives the downstream 
activation of cGMP-dependent protein kinase type I (PKG). 
This leads to inhibition of the calcineurin-nuclear factor of 
activated T cells (NFAT) signaling pathway, which negatively 
regulates cardiac myocyte hypertrophy. This highlights the 
antihypertrophic effect of BNP11 (Fig. 2).
Moreover, BNP plays a crucial role in regulating blood 
pressure levels by mediating diuresis, natriuresis, vasodilation, 
and by antagonizing the renin-angiotensin-aldosterone axis. 
FIgUre 2. BNP antihypertrophic signaling pathway. BNP binds preferentially to the natriuretic peptide receptor-A (NPR-A) to 
exert its effect in the regulation of intravascular blood volume and vascular tone. NPR-A is linked to guanylyl cyclase (GC), which 
upon ligand binding upregulates cyclic guanosine monophosphate (cGMP levels). Cyclic GMP is a key second messenger which in 
turn drives the downstream activation of cGMP-dependent protein kinase type I (PKG). This leads to inhibition of the calcineurin-
nuclear factor of activated T cells (NFAT) signaling pathway, which negatively regulates cardiac myocyte hypertrophy. BNP = brain 
natriuretic peptide; Ca2+ = calcium; CaM = calcium-modulated protein (calmodulin); CnB = calcineurin B subunit; Gαs = G pro-
tein αs subunit; Gβγ = G protein βγ dimer; GATA = transcription factor binding to the DNA sequence “GATA”; MEF2 = myocyte 
enhancer factor-2 proteins (a family of transcription factors); P = phosphorus.
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Increasing evidence supports the beneficial effects of BNP 
in attenuating or inhibiting the processes that contribute to 
cardiovascular remodeling, such as hypertrophy and fibrosis.12 
Additionally, it has been shown that in human adipocytes 
where NPR-A is expressed in significant amounts, upon BNP 
binding, cGMP becomes activated and promotes downstream 
lipolysis and mobilization of free fatty acids.13,14 It is interesting 
to note that a recent study suggested that mice hearts lacking 
NPR-A, exhibited marked hypertrophy with interstitial fibrosis 
resembling that seen in human hypertensive heart disease. 
Thus, it can be assumed that BNP can also act as a parac-
rine antifibrotic factor to inhibit the proliferation of cardiac 
fibroblasts.15 Furthermore, several studies have shown that 
natriuretic peptide levels are markedly increased in patients 
experiencing an acute coronary event. Even so, the role of BNP 
in the pathophysiology of acute MI remains to be elucidated. 
Particularly, a study by Kawakami and colleagues suggested 
that increased BNP plasma concentrations three days after 
an acute MI led to increased polymorphonuclear cell infiltra-
tion in the infarct area in BNP-transgenic mice compared to 
non-transgenic mice. This caused increased matrix metal-
loproteinase (MMP)-9 release by the stimulated neutrophils, 
and subsequently an increased risk of myocardial rupture in 
BNP-transgenic mice.16 On the other hand, researchers have 
shown that administration of ANP at the time of reperfusion 
may exert cardioprotective effects against myocardial reperfu-
sion injury in an acute coronary syndrome. This is attributed 
to ANP’s ability to limit adhesion of polymorphonuclear 
neutrophils to hypoxic endothelial cells, thus decreasing their 
activation and their MMP-9 releasing properties17 (Table 1). 
A great bulk of data has been published regarding the 
metabolism and degradation of natriuretic peptides. From 
these reports, it is clear that C-type natriuretic peptide recep-
tor, which binds ANP as well as BNP, is the most widely and 
abundantly expressed natriuretic peptide receptor, and is be-
ing involved in the systemic clearance of natriuretic peptides 
from the circulation, via a receptor-mediated internalization 
and degradation process. Notably, C-type natriuretic peptide 
receptor has only a short cytoplasmic domain with no gua-
nylyl cyclase activity. Kidney glomeruli express high levels of 
C-type natriuretic peptide receptor and BNP highly depends 
on renal function for its clearance.18 Specifically, it is well 
acknowledged that BNP and its cleavage equivalent amino 
terminal pro-B-type natriuretic peptide (NT-pro-BNP) are 
small molecular weight proteins, that are filtered relatively 
freely by the glomeruli and catabolized by tubular epithelial 
cells without any other processing, such as tubular secretion 
or active reabsorption, and return into the circulation. From a 
clinical point of view, it has been suggested that BNP concen-
trations are higher in heart failure patients and hypertensive 
subjects within the same range of glomerular filtration rate 
which strengthens the fact that these concentrations may 
reflect cardiac production rather than impaired clearance.19,21 
In addition, to C-type natriuretic peptide receptor -mediated 
internalization, BNP is also metabolized by extracellular 
proteases.19 Neprilysin (NEP), a neutral endopeptidase, is an 
extracellular protease that degrades endogenous vasoactive 
peptides, including natriuretic peptides. Interestingly, NEP 
cleaves human BNP at Met5-Val6 and Arg17-Ile18 residues, 
but not at the conserved Cys10-Phe11 bond, as occurs with 
ANP and CNP cleavage.20 Inhibition of NEP increases the 
levels of natriuretic peptides, countering the neurohormonal 
overactivation that contributes to vasoconstriction, sodium 
retention and maladaptive remodeling.19,21,22
In recent years, McMurray et al suggested that valsartan/
sacubitril (brand name Entresto, previously known as LCZ696, 
a mixture of the angiotensin receptor blocker valsartan and the 
neprilysin inhibitor sacubitril), a combination also described 
as an “angiotensin receptor-neprilysin inhibitor” (ARNi), is 
superior to angiotensin converting enzyme (ACE) inhibition 
alone in reducing the risk of death and hospitalization for heart 
failure patients with a reduced left ventricular ejection frac-
tion. The same study provided strong evidence that an ARNi 
is superior to inhibition of the renin-angiotensin system alone 
(enalapril) in patients with chronic heart failure, which further 
supported the replacement of ACE inhibitors or angiotensin II 
receptor blockers (ARBs) with an ARNi in the management 
of chronic heart failure.23
Furthermore, in 2001, nesiritide, a recombinant human 
BNP, was approved by the uS Food and Drug Administration 
for early relief of dyspnea in acute heart failure. However, 
several meta-analyses raised concerns regarding the renal 
tAble 1. Physiological Actions of Brain Natriuretic Pep-
tide (BNP)
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is easy and inexpensive to perform in clinical settings since 
researchers have developed a specific radioimmunoassay for 
human BNP with the use of a monoclonal antibody modeling 
it on a radioimmunoassay for ANP.29 Observations from 1,586 
patients presenting with dyspnea in the emergency setting in 
seven different departments across the uSA, led to the use 
of 50 pg/mL as the cutoff BNP level, with low values shown 
to be highly sensitive at ruling out disease, whereas values 
above this level were found to be the strongest independent 
predictor of heart failure.30
Additionally, another study conducted by Dao et al re-
cruited 250 patients presenting to the urgent-care area of the 
San Diego Veteran’s Health Care System with acute dyspnea as 
the chief complaint.31 BNP plasma concentrations were meas-
ured in all patients and emergency department physicians were 
blinded to the results. Consequently, two cardiologists (also 
blinded to BNP levels) reviewed all medical records of each 
patient retrospectively, and made independent initial assess-
ments on whether patients’ presenting dyspnea was secondary 
to heart failure. Researchers concluded that the mean plasma 
BNP level was higher in patients diagnosed with heart failure. 
Specifically, at a blood concentration of >80 pg/mL, BNP was 
considered as an accurate predictor of the presence of heart 
failure (95%), whereas measurements below this cut-off value 
had a high negative predictive value (98%). Thus, BNP was 
found to be a sensitive and specific test for the diagnosis of 
heart failure in the emergency setting.31
Importantly, it should be noted that the European guide-
lines for the diagnosis and treatment of acute and chronic 
heart failure propose a diagnostic algorithm or flow-chart for 
patients with suspected heart failure.32 They recommend that 
BNP and NT-pro-BNP levels should be considered in order 
to exclude alternative causes of dyspnea (if the level is below 
the exclusion cut-off point: BNP <100 pg/mL, NT-proBNP 
<300 pg/mL) and to obtain prognostic information (Class 
IIa, Level C recommendation). For patients presenting in a 
non-acute setting, a lower exclusion natriuretic peptide cut-off 
point should be used to prevent a ‘false-negative’ diagnosis of 
heart failure (BNP <35 pg/m or NT-proBNP <125 pg/mL).32
b N P  A s  A  P r e D I c t O r  I N  P A t I e N t s 
w I t h  c h r O N I c  h e A r t  F A I l U r e
Brain natriuretic peptide (BNP), as well as its N-terminal 
peptide (NT-pro-BNP), are considered to be critical for the 
prognosis of heart failure progression and outcomes. Tsu-
tamoto et al demonstrated for the first time that increased 
plasma BNP levels may be a critical prognostic predictor 
of heart failure progression in patients with left ventricular 
dysfunction.33 Moreover, BNP measurement was found to be 
a better and independent predictor when used with hemody-
namic parameters, such as pulmonary capillary wedge pressure 
toxicity and mortality associated with the use of nesiritide in 
patients with acute heart failure, as well as the increased rates 
of hypotension observed in these patients.24
Summarizing, it is without question that both an angioten-
sin receptor - neprilysin inhibitor (ARNI), as well as nesiritide, 
a recombinant human BNP, have shown much potential in 
becoming the next big thing in the field of cardiovascular 
therapeutics. However, further research is needed to elucidate 
their clinical usefulness in patients with heart failure.
M e A s U r e M e N t  O F  b N P  l e v e l s  
A N D  A c c U r A c y  I N  t h e  D I A g N O s I s  
O F  h e A r t  F A I l U r e 
Heart failure is a complex chronic and progressive clinical 
syndrome where the heart cannot meet the increased metabolic 
demands of the body. It is a major cause of hospitalization and 
death and it affects approximately 2.3% of the population in 
the united States, particularly the elderly, representing thus a 
growing clinical and economic burden. Interestingly, hospital 
admissions due to heart failure have increased over the past 
years.25 Heart failure is difficult to diagnose, and has always 
been a challenge for clinicians worldwide. There is increasing 
evidence that BNP is synthesized in the heart as a response 
to cardiac stress and neurohormonal activation. In particular, 
BNP levels are found to be elevated in patients suffering from 
congestive heart failure. In addition, the importance of BNP 
and its N-terminal peptide (NT-pro-BNP) in the evaluation 
of patients with acute symptoms, such as dyspnea in the emer-
gency department, has been documented.26 A recent diagnostic 
accuracy study, conducted by Zaphiriou et al in the uK, was 
designed to determine the diagnostic accuracy of BNP and NT-
proBNP plasma measurements in 306 patients with suspected 
heart failure, referred by their general practitioners. This 
study confirmed the importance of BNP and its N-terminal 
peptide measurements as a rule-out test for the diagnosis of 
heart failure in the referred patients. Furthermore, a simple 
classification of the 12-lead ECG into normal or abnormal in 
the same study, added little value to ruling out heart failure 
in these circumstances.27 Moreover, a meta-analysis denotes 
BNP to be an accurate biomarker of heart failure. Pooling 
data from the 20 studies included, researchers concluded that 
using a cut-off value of 15 pmol/L achieves high sensitivity.28 
BNP measurements below this cut-off excluded diagnosis in 
patients with suspected heart failure symptoms. It is critical 
to note that measurement of BNP plasma levels may play a 
significant role in the diagnosis of patients with diastolic heart 
failure, since the diagnostic accuracy of BNP was observed to 
be greater when the definition of disease used as the refer-
ence standard patients who were diagnosed as having heart 
failure with preserved left ventricular ejection fraction.28 
Apart from this, we should note that testing of BNP levels 
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and left ventricular ejection fraction, to assess mortality in the 
same group of patients, compared to the plasma ANP level. 
As such, BNP and NT-pro-BNP neurohumoral factors are 
suggested as sensitive and promising biomarkers reflecting left 
ventricular dysfunction or damage, since BNP is ventricular 
in origin, with the latter being slightly superior.33 In detail, 
scientists concluded that even the diagnostic and prognostic 
utility of NT-pro-BNP appears to be equivalent to BNP in the 
clinical setting, there are some biologic differences between 
them that render the N-terminal peptide a more accurate index 
of ventricular stress and therefore a better predictor of heart 
failure prognosis. It has been showed that NT-pro-BNP is not 
degraded in the blood circulation, and its structure remains 
stable even in the serum. Its half-life is approximately 1 to 2 
hours, which is longer than the half-life of BNP. Conceivably, 
this leads to higher NT-pro BNP levels in the circulation and 
slower fluctuations than BNP.34
Additionally, an observational study monitored 325 pa-
tients presenting with dyspnea, as the major manifestation of 
heart failure, in the emergency department over a six-month 
follow-up period.35 Subsequently, they concluded that higher 
BNP plasma levels at the emergency department were as-
sociated with cardiovascular events and progressively worse 
outcomes over the same period.35 In recent years, Koglin et al 
designed a prospective cohort study to assess the relationship 
between plasma BNP values and risk stratification in patients 
diagnosed with congestive heart failure and who were consid-
ered to be at high risk for experiencing cardiac events, over a 
course of 398 days.36 The results reinforced the usefulness of 
plasma BNP measurements as a screening tool for prognosis 
of heart failure progression and risk segregation, eliminating 
simultaneously the need for more invasive and expensive 
cardiac tests.36 Similarly, another study was conducted in 452 
patients with a left ventricular ejection fraction <35%, as-
sessed by radionuclide ventriculography, to identify the role 
that BNP levels may play in predicting sudden cardiac death 
in this group of subjects, probably attributable to ventricular 
arrhythmias.37 Following these patients for up to 3 years, they 
established BNP plasma levels as the only predictor of sudden 
cardiac death, with the 130 pg/mL being the cutoff value for this 
study.37,38 Besides, Japanese scientists followed 290 consecu-
tive patients with asymptomatic or minimally symptomatic left 
ventricular dysfunction for a mean period of 812 days in order 
to assess the plasma BNP level as an independent predictor 
of morbidity and mortality in this group of patients.39 Blood 
samples were collected from all patients and plasma BNP 
levels as well as levels of other neurohumoral factors, such as 
ANP, norepinephrine, angiotensin II, and endothelin-1 were 
measured. Results indicated that plasma BNP concentration is 
a more useful biomarker for predicting morbidity and mortality 
than the other neurohumoral factors, and provides important 
information regarding hemodynamic parameters such as 
ejection fraction, left ventricular end-diastolic pressure, and 
left ventricular end-diastolic volume index, since the cardiac 
ventricles are the primary source of its blood level.39 Finally, 
not only BNP is an important predictor of morbidity and 
mortality in patients with chronic symptomatic heart failure, 
but also predicts all-cause mortality in the general popula-
tion and in those with no evidence of left ventricular systolic 
dysfunction40 (Table 2).
s c r e e N I N g  O F  A s y M P t O M A t I c 
s U b j e c t s  A t  r I s K  F O r  h e A r t 
F A I l U r e ,  s U c h  A s  t h e  e l D e r l y , 
h y P e r t e N s I v e  s U b j e c t s ,  D I A b e t I c s 
O r  t h O s e  w I t h  A s y M P t O M A t I c 
c O r O N A r y  A r t e r y  D I s e A s e
From a different perspective, it has been demonstrated 
that plasma BNP calculations may also reflect the risk for 
cardiovascular events, not only in heart failure patients with 
severe dyspnea, but also in asymptomatic subjects at risk for 
cardiac pump failure, such as the elderly, diabetics, patients 
with hypertensive heart disease, as well as those with asymp-
tomatic coronary artery disease.
Specifically, a randomized clinical trial comprising 1,257 
patients was designed to examine the cost-effectiveness of us-
ing plasma BNP as a screening test for assessing left ventricu-
lar systolic dysfunction in the general population, to further 
reduce the need for echocardiograms.41 Consequently, BNP 
BNP = brain natriuretic peptide; HF = heart failure
tAble 2. Prognostic Value of BNP
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was found to have high sensitivity in detecting left ventricular 
systolic dysfunction in low and high-risk patients with ischemic 
heart disease.42 Indeed, appropriate treatment of heart fail-
ure led to improved survival and thus, an early diagnosis and 
proper decision making are therefore beneficial. Japanese 
researchers conducted a multiple regression analysis to evalu-
ate systolic and diastolic cardiac function in seemingly healthy 
asymptomatic subjects by measuring BNP levels. In order to 
come to a conclusion regarding their assumption, they com-
pared BNP levels with other cardiac indices obtained from 
chest radiographs, electrocardiograms and echocardiograms. 
Derived data from a pool of 294 asymptomatic patients showed 
a significant correlation between echocardiographic param-
eters and increased BNP plasma concentrations and both 
left ventricular systolic and diastolic functions, highlighting 
thus the effectiveness of BNP as a screening tool to reflect 
both the systolic and diastolic function.42 Furthermore, left 
ventricular wall thickness, blood pressure measurements, and 
serum creatinine levels were found to correlate with raised 
BNP concentrations.42 Cardiologists have also reported that 
by performing a simple radioimmunoassay for BNP, clinicians 
can rapidly and reliably detect the presence of significant dias-
tolic filling abnormalities on echocardiography. Interestingly, 
low BNP concentrations along with normal echocardiogram 
performance may be able to rule out diastolic dysfunction, 
whereas raised BNP values in heart failure patients with pre-
served ejection fraction, especially the elderly, are found to 
be associated with diastolic dysfunction on Doppler studies.43 
More specifically, it has been shown that screening for asymp-
tomatic left ventricular dysfunction is of particular importance 
as its prevalence alone ranges from 0.9 to 12.9%, depending 
on standard risk.44 Indeed, in the general population, patients 
with increased plasma BNP levels exhibit significant morbid-
ity and mortality and thus, accurate screening of subclinical 
disease is necessary.45-48
F U t U r e  D I r e c t I O N s
Surely, BNP may be a promising biochemical marker of 
effective blood pressure management, since multiple studies 
have suggested that its measurement probably could be a guide 
of hypertension management and target organ protection. 
However, further cutting-edge research is needed to elucidate 
the role of BNP plasma concentrations in the assessment of 
cardiovascular risk and mortality.
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